ENLV

Enlivex Ltd. (ENLV) - Form 20-F Summary

Business Context and Reporting Period

Company: Enlivex Ltd. (formerly Enlivex Therapeutics Ltd.)
Reporting Period: Fiscal year ended December 31, 2025
Business Model: Enlivex operates a dual strategy combining clinical-stage immunotherapy development with a cryptocurrency treasury model.

• Clinical Operations: Developing Allocetra™, a macrophage reprogramming cell therapy for inflammatory conditions, primarily osteoarthritis. The company has no commercial product revenue.
• Treasury Operations: In November 2025, the company adopted a treasury strategy centered on the RAIN token (a decentralized prediction market protocol). Substantially all treasury reserves are held in RAIN and related derivatives.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The 2025 Net Income is driven entirely by non-cash, unrealized gains of $1.63 billion from the appreciation of digital assets and the RAIN purchase option. Operating cash flow remains negative at $(10.42) million.

Material Changes vs. Prior Period

• Strategic Pivot: Transitioned from a pure-play biotech to a hybrid model with a significant digital asset treasury following a $212 million private placement in November 2025.
• Asset Composition: Digital assets and the RAIN Option now represent approximately 99.5% of total assets, compared to zero in 2024.
• Profitability: Shifted from a net loss of $15 million in 2024 to a net income of $1.24 billion in 2025, solely due to fair value adjustments on digital assets.
• Operating Expenses: Research and Development (R&D) expenses decreased by 13% to $9.2 million, while General and Administrative (G&A) expenses increased by 18% to $5.8 million.

Guidance, Outlook, and Risks

Clinical Outlook:

• Phase IIb global trial for Allocetra™ in knee osteoarthritis received FDA clearance in March 2026.
• Topline data for the Phase IIb trial is expected in Q2 and Q3 of 2027.
• The company plans to seek external collaborations for the sepsis indication rather than internal development.

Treasury Outlook:

• The company intends to hold RAIN as a long-term treasury reserve asset.
• Management believes existing resources (cash and liquid digital assets) are sufficient to fund operations through the end of 2027.

Key Risks:

• Digital Asset Volatility: Financial results are highly sensitive to the market price of RAIN. A decline in RAIN's price would materially reduce asset values and reported earnings.
• Liquidity: Digital assets are less liquid than cash. The company relies on converting RAIN to stablecoins (USDT) and then to fiat currency to meet obligations.
• Regulatory Uncertainty: Risks regarding the classification of digital assets as securities, potential regulatory actions against prediction markets, and tax implications.
• Geopolitical: Operations are based in Israel, exposing the company to regional instability and military conflict.

Investor Verification Checklist

• Asset Valuation: Verify the fair value methodology for RAIN tokens and the RAIN Option (Level 1 vs. Level 2 inputs) and the specific exchanges used for pricing.
• Liquidity Strategy: Confirm the company's ability to convert digital assets to fiat currency quickly enough to cover operating cash burn without forced sales at depressed prices.
• Clinical Milestones: Monitor the timeline and results of the Phase IIb osteoarthritis trial, as this remains the only path to operational revenue.
• Regulatory Status: Track any SEC or CFTC guidance regarding the RAIN token and prediction markets, as well as tax treatment of digital asset gains in Israel and the U.S.
• Debt Obligations: Review the terms of the $21 million convertible note issued in March 2026, specifically regarding collateralization by digital assets and conversion triggers.